In the Lancet Child & Adolescent Health Commission on the future of neonatology, Daniele De Luca and colleagues call for ...

The discovery could significantly reduce the production costs of fuels, chemicals, and materials. A research team from the University of Minnesota Twin Cities College of Science and Engineering and ...

Viking offers asymmetric upside in GLP-1 drugs with positive trial data, strong cash, and buyout potential despite biotech ...

Two experts discussed innovative trial designs in rare disease research, common challenges and the potential of AI to enhance ...

A team of researchers from the University of Minnesota Twin Cities College of Science and Engineering and the University of ...

A Mediterranean-style diet, low-impact activity, and targeted nutraceuticals co-managed with diabetes care produced a 33% ...

A team of researchers from the University of Minnesota Twin Cities College of Science and Engineering and the University of Houston’s Cullen College of Engineering has discovered and measured the ...

Metsera's MET-097i cut weight up to 14% in Phase 2b trials, with manageable side effects, as the company targets a global ...

In a groundbreaking development, Pfizer's strategic investment of $4.9 billion in obesity startup Metsera is yielding promising results. The latest Phase IIb trial of MET-097i, a glucagon-like peptide ...

Pfizer’s $4.9bn bet on obesity startup Metsera is looking promising, with 14.1% weight loss reported in a Phase IIb trial. In the VESPER-1 trial (NCT06712836), MET-097i, a glucagon-like peptide-1 ...

Placebo-subtracted mean weight loss up to 14.1%after 28 weeks with no plateauPotential for best-in-class tolerability with minimal diarrhea ...